TX-FLUENCE
9.5.2022 14:02:07 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its sponsorship of Wageningen University & Research’s (WUR) third Autonomous Greenhouse Challenge in the Netherlands. For the first time in the challenge’s history, WUR leveraged a broad-spectrum LED-only lighting system—specifically Fluence’s VYPR 3p solution—instead of high-pressure sodium (HPS) fixtures. WUR also implemented Fluence’s innovative lighting control solution, Wireless Flex Dimming, into the facility.
Wageningen University & Research is dedicated to researching the future of agriculture by exploring autonomous greenhouse technology, climate control, crop modeling, advanced sensors, data intelligence, computer vision and robotics. Beginning in June 2021, WUR organized its third Autonomous Greenhouse Challenge to task different international teams with sustainably growing vegetables in a fully automated greenhouse environment.
“We expect that food production in greenhouse horticulture can be further improved by adding more artificial intelligence to the agricultural industry,” said Silke Hemming, who leads the scientific research team for greenhouse technology at WUR, in a statement . “We make connections with international partners through this unique challenge, so that we can take major steps.”
One of the challenges growers face when transitioning from HPS to LED luminaires is that a typical HPS system is limited in its dimming capabilities, unlike LED technology. By leveraging state-of-the-art, qualified Bluetooth mesh technology enabled by Technology Partner SILVAIR, Fluence’s Wireless Flex Dimming solution allows growers to have precise control of dim light levels. By connecting the VYPR top light fixtures to the climate computer through Wireless Flex Dimming, the participants were empowered to implement advanced lighting control strategies that maximized plant growth and quality.
“In any greenhouse or controlled environment, the reliability of a cultivation system is paramount,” said Theo Tekstra, Fluence’s technical director for Europe, Middle East and Africa. “Wireless Flex Dimming enables growers to simplify installation and gain solid wireless control of their light levels, whether in an autonomous scientific experiment or a large-scale greenhouse. We are now implementing this technology for customers with more than 7,000 connected fixtures.”
WUR’s Autonomous Greenhouse Challenge also seeks to discover how artificial intelligence can play a role in the future of cultivation, including how to reduce energy input and cost.
“The complete cultivation process is handled by AI and algorithms developed by the teams,” Tekstra added. “One important input factor is the strong fluctuations in high energy prices. Fluence’s Wireless Flex Dimming integration with the Ridder climate computer allows the teams to modulate the lights within their lighting strategy algorithms to optimize energy costs. Fluence’s mission is to help the world grow smarter—something these incredible teams are tackling head-on. We are delighted to support WUR and this initiative with our advanced lighting solutions.”
Fluence continues to demonstrate how secure, intelligent lighting solutions based on the latest technology innovations can add value to the global horticulture industry. The Wireless Flex Dimming Receiver has been awarded PSA Certified™ Level 1 (an independent measurement of security best practices spearheaded by Arm) from Riscure. PSA Certified is recognized by the DesignLights Consortium as an approved cybersecurity standard for networked lighting control systems.
Results from the challenge will be published in July 2022. To follow the competing teams’ progress, visit WUR’s greenhouse challenge dashboard here . For more information on Fluence and its portfolio of controls and luminaires, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
